Search - tctmd.com

Displaying 1 - 20 of 27

Sort: Relevancy | Date

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

News Daily News

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

Yael L. Maxwell

October 24, 2025

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

News Daily News

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Michael O'Riordan

September 18, 2025

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

GLP-1s Reduce Limb and Cardiac Events in Peripheral Artery Disease

News Daily News

GLP-1s Reduce Limb and Cardiac Events in Peripheral Artery Disease

June 12, 2025

Newer Weight-Loss Drugs Not Cost-effective at Current Prices

News Daily News

Newer Weight-Loss Drugs Not Cost-effective at Current Prices

Michael O'Riordan

March 18, 2025

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

News Daily News

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

October 23, 2024

‘Provocative’ Projections See Semaglutide Slashing CV Events in Adults With ASCVD

News Daily News

‘Provocative’ Projections See Semaglutide Slashing CV Events in Adults With ASCVD

June 27, 2024

Bariatric Surgery Reduces Hard Events in Obese Patients With Sleep Apnea

News Daily News

Bariatric Surgery Reduces Hard Events in Obese Patients With Sleep Apnea

Michael O'Riordan

June 21, 2024

FDA Grants MACE Reduction Indication for Semaglutide

News Daily News

FDA Grants MACE Reduction Indication for Semaglutide

March 08, 2024

One in Three Overweight MI Patients May Benefit From Semaglutide

News Daily News

One in Three Overweight MI Patients May Benefit From Semaglutide

February 26, 2024

Universal Risk Tool Works Well in Both Primary and Secondary Prevention

News Daily News

Universal Risk Tool Works Well in Both Primary and Secondary Prevention

Michael O'Riordan

February 01, 2024

Top General Cardiology and CVD Prevention News of 2023

News Daily News

Top General Cardiology and CVD Prevention News of 2023

Yael L. Maxwell

January 03, 2024

Who Benefits Most From Semaglutide and How Long Will That Take?

News Daily News

Who Benefits Most From Semaglutide and How Long Will That Take?

December 19, 2023

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

News Daily News

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Michael O'Riordan

September 29, 2023

SELECT: Semaglutide Cuts CV Events in Adults With Overweight or Obesity

News Daily News

SELECT: Semaglutide Cuts CV Events in Adults With Overweight or Obesity

August 08, 2023

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

Sugar Substitute Erythritol Linked to Cardiac Risk

News Daily News

Sugar Substitute Erythritol Linked to Cardiac Risk

Yael L. Maxwell

March 15, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.